Core Insights - The latest version of the medical insurance drug list will be implemented on January 1, 2026, with significant updates aimed at improving access to essential medications for insured individuals [1]. Group 1: New Drug Additions - A total of 114 new drugs have been added to the list, with 50 classified as first-class new drugs, marking a record high in both quantity and proportion [2]. - New drugs include treatments for critical conditions such as triple-negative breast cancer and pancreatic cancer, as well as medications for chronic diseases and rare diseases [2]. Group 2: Expanded Payment Coverage - The payment scope has been broadened for 65 drugs, with new indications included for reimbursement, such as additional targets for non-small cell lung cancer treatments and expanded age eligibility for certain rare disease medications [3]. - Adjustments have been made to align payment criteria more closely with clinical practices, such as changing the payment range for certain drugs from "previous chemotherapy" to "past chemotherapy" [3]. - Some drugs have had restrictions removed or modified, while ensuring that reimbursement is still aligned with clinical guidelines [3]. Group 3: Drug Removal and Transition Policies - A total of 29 drugs have been removed from the list, primarily those that have been clinically obsolete or not produced for an extended period [4]. - A transition policy has been established for drugs that were removed but had not successfully renewed their contracts, allowing a 6-month period for insured individuals to purchase these drugs at the original reimbursement standards [4].

Core Viewpoint - The implementation of the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)" aims to optimize the drug reimbursement system, enhancing both the efficiency of medical insurance funds and the accessibility of essential medications for the public [1] Group 1: Drug List Changes - The new drug list includes 114 new drugs, with 50 being innovative first-class drugs, while 29 drugs with lower clinical value have been removed, bringing the total to 3,253 drugs [1] - The updated list covers key areas such as oncology, rare diseases, chronic diseases, and pediatric medications [1] Group 2: New Drug Characteristics - Newly included drugs exhibit three significant characteristics: they either fill clinical treatment gaps, are superior alternatives, or offer better cost-effectiveness [1] - Specific examples include new drugs for treating triple-negative breast cancer and pancreatic cancer, which improve affordability and accessibility for patients [2] Group 3: Payment Scope Adjustments - The payment scope for 65 drugs has been revised to better align with clinical realities, such as expanding the use of certain drugs to a broader patient age range [3] - New conditions have been added for some drugs to prevent misuse while ensuring that medical insurance funds are utilized effectively [3] Group 4: Cost Reduction Initiatives - The combination of price negotiations and medical insurance reimbursements is expected to lower the cost of medications for the public [3] - A new "Commercial Health Insurance Innovative Drug List (2025)" has been introduced, including 19 high-value innovative drugs, which complements basic medical insurance and addresses diverse health needs [3] Group 5: Implementation and Accessibility - The medical insurance department has mandated that medical institutions incorporate newly added drugs into their procurement lists by the end of February [4] - A transition policy allows for a 6-month period during which patients can still purchase removed drugs at previous reimbursement rates [4] - A new feature for querying the updated basic medical insurance drug list has been launched on the National Medical Insurance Bureau's WeChat public account [4]

Core Insights - The recent adjustment to the National Medical Insurance Drug List has significantly reduced the costs of long-acting growth hormone treatments, benefiting many families [1] - The new drug list includes a high proportion of innovative drugs and aims to enhance drug accessibility for patients in urgent clinical need [2] Group 1: New Drug Additions - A total of 114 new drugs have been added to the insurance list, covering critical areas such as oncology, chronic diseases, and rare diseases [2] - The average price reduction for newly added drugs exceeds 60%, significantly alleviating the financial burden on patients [2] - Notable new drugs include innovative treatments for triple-negative breast cancer and pancreatic cancer, as well as long-acting growth hormone for children [2] Group 2: Optimization of Existing Drugs - The payment scope for 65 existing drugs has been optimized, including expanded indications for certain medications [3] - Adjustments have been made to ensure that the descriptions of drug payment scopes align more closely with clinical realities [3] Group 3: Policy Measures - The government has implemented a series of policies to ensure that negotiated drugs are effectively integrated into hospitals and accessible to patients [3] - Medical institutions are required to hold pharmacy meetings to incorporate new drugs into their procurement lists by February 2026 [3] Group 4: Industry Impact - The adjustment has led to the removal of 29 drugs that have lower efficacy or better alternatives available, thereby optimizing the use of medical insurance funds [4] - The inclusion of numerous innovative drugs indicates a strengthening of domestic pharmaceutical companies' research and development capabilities [4][5] - Major companies like Heng Rui Medicine and Innovent Biologics have successfully introduced multiple innovative drugs into the new insurance list [5]

Core Insights - The recent adjustment to the National Medical Insurance Drug List has significantly reduced the costs of long-acting growth hormone treatments, benefiting many families [1] - The new drug list includes a substantial number of innovative drugs, with an average price reduction of over 60%, aimed at improving patient access to essential medications [2] Group 1: New Drug Additions - A total of 114 new drugs have been added to the insurance list, covering critical areas such as oncology, chronic diseases, and rare diseases [2] - Notable new drugs include innovative treatments for triple-negative breast cancer and pancreatic cancer, as well as long-acting growth hormone for children [2][4] - The new drugs are characterized by either filling clinical treatment gaps, being superior to existing options, or offering better cost-effectiveness [2] Group 2: Existing Drug Adjustments - The payment scope for 65 existing drugs has been optimized, including expanding the target population for certain medications [3] - Adjustments have been made to align drug descriptions more closely with clinical realities, facilitating easier prescription by healthcare providers [3] Group 3: Policy and Industry Impact - The adjustment aims to optimize the use of medical insurance funds, allowing for the introduction of innovative drugs while removing less effective ones [4] - The removal of 29 drugs primarily targets those with lower cost-effectiveness or available alternatives, with minimal impact on most patients [4] - The inclusion of numerous innovative drugs reflects the strengthening of domestic pharmaceutical companies' R&D capabilities [5] Group 4: Financial Implications - The National Medical Insurance Bureau has adjusted the drug list for eight consecutive years, adding a total of 949 new drugs, with significant financial implications for the pharmaceutical market [5] - The insurance fund has spent over 460 billion yuan on negotiated drug expenditures, driving sales growth exceeding 600 billion yuan [5]

Core Insights - The latest medical insurance drug list has been officially implemented as of January 1, 2026, featuring significant updates that enhance accessibility and affordability for insured individuals [1]. Group 1: New Drug Additions - A total of 114 new drugs have been added to the list, with 50 classified as new category 1 drugs, marking a record high in both quantity and proportion [2][3]. - Notable new drugs include treatments for triple-negative breast cancer, pancreatic cancer, and various chronic conditions, such as long-acting growth hormone injections and diabetes medications [3]. Group 2: Expanded Payment Scope - The payment scope has been broadened to include 65 drugs with new indications, allowing for better access to treatments for conditions like non-small cell lung cancer and rare diseases [4]. - Adjustments have been made to align payment criteria more closely with clinical practices, such as changing the payment criteria for certain drugs to reflect actual treatment scenarios [4]. Group 3: Restrictions and Conditions - New restrictions have been introduced for certain drugs to prevent misuse, ensuring that insurance funds are utilized effectively [5]. - Some drugs have had non-core restrictions removed, but the fundamental usage requirements remain unchanged, emphasizing the need for clinical discretion [5]. Group 4: Structural Adjustments - A total of 29 drugs have been removed from the list, primarily those that have been clinically obsolete or are no longer in production [6]. - A transition period of six months has been established for drugs that were removed but were under negotiation, allowing insured individuals to continue purchasing them at previous reimbursement rates until June 2026 [6]. Group 5: User Accessibility - The National Medical Insurance Bureau has launched a new feature on its WeChat account for users to query the updated basic medical insurance drug list easily [6].

Core Insights - The latest medical insurance drug list will be implemented on January 1, 2026, featuring significant updates that focus on clinical needs and expand access to essential medications [1] Group 1: New Drug Additions - A total of 114 new drugs have been added to the list, with 50 classified as first-class new drugs, marking a record high in both quantity and proportion [1] - Notable new drugs include treatments for triple-negative breast cancer, pancreatic cancer, and long-acting growth hormone injections for children with growth deficiencies [3] Group 2: Expanded Payment Coverage - The payment coverage has been expanded for 65 drugs, with new indications included for existing medications, such as additional targets for non-small cell lung cancer treatments and broader age eligibility for rare disease treatments [4] - Adjustments have been made to payment criteria to better align with clinical practices, such as changing the payment range for certain drugs from "previous chemotherapy" to "past chemotherapy" [4] Group 3: Restrictions and Adjustments - New limitations have been introduced for certain drugs to prevent misuse, ensuring that insurance funds are utilized effectively [5] - Some drugs have had non-core restrictions removed, but the fundamental usage requirements remain unchanged, such as the diabetes medication semaglutide [5] Group 4: Drug List Structure and Transition Policies - The updated list has removed 29 drugs that are either clinically obsolete or have not been produced for an extended period, including several that did not successfully renew their negotiation agreements [6] - A transition policy has been established, allowing a 6-month period for patients to purchase removed drugs at previous reimbursement standards [6] - A new query function for the basic medical insurance directory has been launched on the National Medical Insurance Bureau's WeChat account for easier access to the updated list [6]

Core Insights - The latest medical insurance drug list will be implemented on January 1, 2026, featuring significant updates that benefit insured individuals [1][9]. Group 1: New Drug Additions - A total of 114 new drugs have been added to the list, with 50 classified as first-class new drugs, marking a record high in both quantity and proportion [10]. - New drugs include treatments for critical conditions such as triple-negative breast cancer and pancreatic cancer, as well as medications for growth hormone deficiency in children and diabetes [12]. Group 2: Expanded Payment Coverage - The payment scope has been expanded for 65 drugs, with new indications included for several medications, such as additional targets for non-small cell lung cancer treatment and expanded age eligibility for narcolepsy treatment [4][12]. - Adjustments have been made to payment criteria to better align with clinical practices, such as changing the payment scope for certain drugs from "previous chemotherapy" to "past chemotherapy" [4][12]. Group 3: Drug Removals - A total of 29 drugs have been removed from the list, primarily those that have been clinically obsolete or not produced for an extended period [5][14]. - A transition policy has been established, allowing a 6-month period for insured individuals to purchase removed drugs at the original reimbursement standards [14]. Group 4: Accessibility and User Support - The National Medical Insurance Bureau has launched a new function on its WeChat public account for users to query the updated basic medical insurance directory [8][16].

Core Insights - The latest medical insurance drug list will be implemented on January 1, 2026, featuring significant updates that focus on clinical needs and patient benefits [1] Group 1: New Drug Additions - A total of 114 new drugs have been added to the list, with 50 classified as first-class new drugs, marking a record high in both quantity and proportion [1] - Notable new drugs include treatments for triple-negative breast cancer, pancreatic cancer, and long-acting growth hormone injections for children with growth deficiencies [3] Group 2: Expanded Payment Scope - The payment scope has been broadened to include 65 drugs with new indications, such as additional targets for non-small cell lung cancer and expanded age eligibility for narcolepsy treatment [4] - Adjustments have been made to payment criteria to better align with clinical practices, such as changing the eligibility for certain drugs from "previous chemotherapy" to "prior chemotherapy" [4] Group 3: Restrictions and Adjustments - New limitations have been introduced for certain drugs to prevent misuse, ensuring that insurance funds are utilized effectively [5] - Some drugs have had non-core restrictions removed, but the fundamental usage requirements remain unchanged, such as the diabetes medication semaglutide [5] Group 4: Drug Removal and Transition Policies - A total of 29 drugs have been removed from the list, primarily those that are clinically obsolete or no longer produced [6] - A transition period of six months has been established for patients to continue purchasing removed drugs at previous reimbursement standards [6] Group 5: Accessibility Features - The National Medical Insurance Bureau has launched a new feature on its WeChat account for users to query the updated basic medical insurance directory [6]

Core Insights - The release of the new drug directories marks a significant advancement in China's innovative drug security system, transitioning to a "basic medical insurance + commercial insurance" complementary model, which will notably reduce the medication burden for insured patients, especially those with cancer and rare diseases [3][13][20] - The total number of drugs in the national medical insurance directory has increased to 3,253, with 114 new drugs added and 29 drugs removed, including 19 high-priced innovative drugs included in the commercial insurance directory [3][20] Summary by Sections National Medical Insurance Directory - The 2025 National Medical Insurance Drug Directory includes 114 new drugs, with 111 being newly launched in the last five years, marking a historical high for innovative drugs [4][14] - The approval-to-coverage timeline for innovative drugs has been significantly shortened, exemplified by the rapid inclusion of the domestic targeted drug for triple-negative breast cancer, which was approved in November 2024 and will be available for clinical use by October 2025 [5][15] Commercial Health Insurance Directory - The first commercial health insurance innovative drug directory aims to address the accessibility of high-priced innovative drugs that exceed the basic medical insurance's affordability [8][17] - This directory includes 19 drugs, featuring advanced therapies such as CAR-T cell therapy and treatments for Alzheimer's and rare diseases, with costs often reaching hundreds of thousands [17][18] Policy Innovations - The "three exclusions" policy allows drugs in the commercial insurance directory to be exempt from basic medical insurance self-payment rate indicators, centralized procurement monitoring, and disease-based payment ranges, encouraging the development of insurance products that cover these high-priced drugs [18][20] - The strict admission standards for the commercial insurance directory ensure that only drugs with high innovation and clinical value are included, with a success rate of 88.19% for negotiations, indicating a rigorous selection process [16][19] Overall Impact - The dual directory adjustment represents a milestone in China's healthcare system, establishing a multi-tiered medical security framework that combines basic insurance, commercial insurance, and medical assistance [10][20] - The adjustments aim to accelerate the inclusion of innovative drugs in basic medical insurance while creating conditions for more innovative drugs to enter the market, ultimately enhancing patient access to life-saving medications [20][21]

Core Insights - The National Healthcare Security Administration (NHSA) has released the 2025 National Medical Insurance Drug List, adding 114 new drugs, including 50 innovative drugs of Class A, and 19 drugs included in the first commercial insurance innovative drug list [1][4] Summary by Sections New Drug Additions - The 2025 National Medical Insurance Drug List primarily adds chemical drugs, with a rapid increase in biological products and some traditional Chinese medicine [1] - Out of the 114 new drugs, 112 were included through negotiation and bidding, while 2 were directly included from national procurement [1] - A total of 111 new drugs were approved in the last five years, with the number of Class A innovative drugs reaching a historical high of 50 [1] Financial Impact - As of October 2023, the NHSA has paid over 460 billion yuan for drugs under agreement, benefiting over 1 billion patients and driving related sales exceeding 670 billion yuan [2] - Basic medical insurance covers approximately 44% of the costs for innovative drugs, while commercial insurance covers about 7% [2] Evaluation and Selection Criteria - The selection process for new drugs has seen a low pass rate during expert reviews, with only 127 out of 311 drugs passing to the negotiation table this year [2] - Some drugs were not favored due to "involutionary innovation," where the clinical value does not significantly improve compared to existing drugs [3][4] - To be included in the list, drugs must meet at least one of three criteria: filling clinical gaps, superior efficacy, or better cost-effectiveness [4] Commercial Insurance Innovations - The newly introduced commercial health insurance innovative drug list emphasizes drug innovation and clinical value, with 19 out of 141 submitted drugs successfully negotiated for inclusion [5] - The drugs in the commercial insurance list include 9 Class A new drugs, addressing gaps in basic medical insurance coverage [5] Future Directions - The NHSA plans to continue annual adjustments to the drug list to meet evolving clinical needs and incorporate advancements in medical technology [6] - The focus will be on supporting domestic and innovative drugs, enhancing collaboration between commercial insurance and innovative pharmaceutical companies [6]